Abstract
Lung cancer induced by oncogenic mutations of the KRAS GTPase is a very frequent disease, for which there are currently no effective therapies. Although these mutations are closely linked to oncogenesis, different approaches to inhibit RAS proteins directly have previously failed. Therefore, for better therapeutic targets for lung cancer to become available, it is necessary to identify th…